Aryl Substituted Benzimidazolones as Potent HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors
作者:Nicole Pribut、Adriaan E. Basson、Willem A. L. van Otterlo、Dennis C. Liotta、Stephen C. Pelly
DOI:10.1021/acsmedchemlett.8b00549
日期:2019.2.14
generation benzimidazolone inhibitors were found to be potent inhibitors of wild-type HIV reverse transcriptase but were ineffective in the presence of common resistance mutations such as K103N and Y181C. A second generation benzimidazolone inhibitor (compound 42) not only showed inhibitory activity against wild-type HIV but also remained active against HIV containing the K103N, Y181C, and K103N/Y181C drug
自从发现HIV作为AIDS的病因以来,该病毒每年已经感染了数百万人。幸运的是,通过使用HAART,可以将感染者的病毒血症抑制到低于可检测的水平,这可以显着改善他们的生活质量并预防AIDS的发作。但是,HAART不能治愈,与依从性和耐药性有关的问题可能导致病毒血症再度出现,艾滋病的发展并最终导致死亡。为了满足对具有抵抗携带普遍耐药突变的病毒活性的新型有效抗逆转录病毒药的开发的紧迫需求,我们设计了两代苯并咪唑酮衍生物作为HIV非核苷逆转录酶抑制剂。发现第一代苯并咪唑酮抑制剂是野生型HIV逆转录酶的有效抑制剂,但在常见的抗性突变(例如K103N和Y181C)存在下无效。第二代苯并咪唑酮抑制剂(化合物42)不仅显示出对野生型HIV的抑制活性,而且仍然对包含K103N,Y181C和K103N / Y181C耐药突变的HIV保持活性。